Tags Posts tagged with "marijuana stock"

marijuana stock

0 1508

Rocky Mountain High Brands Discusses Series A Preferred Restructuring

DALLAS, March 17, 2017 (GLOBE NEWSWIRE) — Rocky Mountain High Brands, Inc. (RMHB), a fully reporting consumer goods company specializing in hemp-infused food and beverage products and a naturally high alkaline water, offered an explanation of its recent move to increase the voting and conversion rights of its Series A Preferred Stock.

Michael Welch, President and Chief Executive Officer of Rocky Mountain High Brands, Inc., said, “With the recent acquisition by LSW Holdings, LLC of the Company’s Series A Preferred Stock, we have reviewed our equity structure and are making changes to it to both protect the Company and to provide for its future growth. The Series A Preferred Stock is the Control Block for the Company. It has special rights associated with it and is not designed or intended to be converted to Common Stock. Changes to its voting rights and conversion rights were made to ensure that LSW Holdings maintains control of the Company in the event of corporate actions such as a merger/acquisition or hostile takeover.”

Welch continued, “Lily Li and other principals and representatives of LSW Holdings were in Dallas this week to meet our Rocky Mountain High team and discuss future plans for the Company. With the opportunities that LSW Holdings will bring into the Company, we need to protect the Company and its shareholders from a hostile takeover or any other uninvited action not in the best interest of the Company or its shareholders. The restructuring of the Series A Preferred Stock voting and conversion rights are a part of that plan.”

About Rocky Mountain High Brands:

ROCKY MOUNTAIN HIGH BRANDS, INC., is a consumer goods company specializing in brand development of health conscious, hemp-infused food and beverage products. The Company currently markets a lineup of four naturally flavored hemp-infused beverages (Citrus Energy, Black Tea, Mango Energy and Lemonade) and a low calorie Coconut Lime Energy drink. Rocky Mountain High Brands also offers hemp-infused 2oz. Mango Energy Shots and Mixed Berry Energy Shots. The Company recently launched a naturally high alkaline spring water, Eagle Spirit Spring Water.

For interested investors, our stock symbol is RMHB.

For ordering information please visit: LiveRockyMountainHigh.com

For corporate information please visit: RockyMountainHighBrands.com

For information on our high alkaline water visit: EagleSpiritWater.com

For Rocky Mountain High Distribution Contact:

Chuck Smith (972) 955-0964
chuck@rockymountainhighbrands.com

Visit us on Facebook: https://www.facebook.com/rockymountainhighbrands?fref=nf

Visit us on Twitter:
#GetYourHempOn

Visit us at Investors Hangout: http://investorshangout.com/Rocky-Mountain-High-Brands-Inc-RMHB-69150/

Investors Hangout is the only authorized Investors blog page for Rocky Mountain High Brands, Inc.

Safe Harbor Act: This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involves risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic business conditions and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

1 12208

How Have Marijuana Stocks Performed Post Trump?

Here we are, the official inauguration day of our 45th President of the United States of America, Donald Trump. A lot has been said about him over the last few years during the election race but what many may not have expected was a clear “Trump Bump” for marijuana stocks.

As we’ve said in the past, a lot of marijuana stocks are event driven. Going all the way back to 2014 and during the years to follow, catalysts in the cannabis market can be tied to actual events in many cases. For this most recent jump in marijuana stock prices, we see that an election year and a not so conservative President may be the event to thank for this.

In this article we’ll briefly explore some of the most active and most bullish marijuana stocks in the market to give a clear example of “where we’ve been” and what we might be able to look forward to as to “where we’re going”.

OWC Pharmaceutical Research Corp. (OWCP) 3,512%

This company has been building steam since October and just recently went into overdrive to all time highs. Through its subsidiary, One World Cannabis, the Israeli-based company develops cannabinoid-based therapies that target different medical conditions. This was another cannabis biotech company that saw the impact of Trump coming into office instead of Clinton (who was very bearish on biotech).

In late October just before the elections, OWCP saw its first noticeable move from under $0.03 and initially ran to highs of $0.215. Following the consolidation period heading into the end of the year (as most marijuana stocks saw), January opened the door for this stock to run as high as $0.95

OWCP_Marijuana_Stocks

 

Rocky Mountain High Brands (RMHB)
271%

We’ve reported on this company and followed it for a few years. Even before when it was “Totally Hemp Crazy (THCZ)” this stock saw one of the biggest breakouts that we’ve every witnessed. It went from sub penny to highs of 0.32 within weeks. Now it appears that chart has demonstrated a similar Trump Bump that many of the other marijuana stocks have also seen.

In early October, volume began to build, RMHB ran from $0.031 to highs of $0.07. After consolidating back to 0.03-0.04, RMHB has now seen its 2017 rally trigger and has now managed to run past $0.11. Rocky Mountain is a consumer goods company specializing in brand development of health conscious, hemp-infused food and beverage products. The Company currently markets a lineup of four naturally flavored hemp-infused beverages (Citrus Energy, Black Tea, Mango Energy and Lemonade) and a low-calorie Coconut Lime Energy drink. Rocky Mountain High Brands also offers hemp-infused 2oz. Mango Energy Shots and Mixed Berry Energy Shots, as well as a Relaxation Brownie.

Marijuana Stock

Ubiquitech Software Corp. (UBQU)
304%

UBQU follows a similar trend where even though it hasn’t broken above its year end highs, the stock has seen a reversal that started at the beginning of 2017. A lot of questions were raised regarding a previously announced name change and recently the company gave clear guidance on this for 2017 that has brought attention back to the stock from market bulls. Its final name change will be Endo BioSciences Inc., and HempLife Today™ will continue to be the main subsidiary of the company.

HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; its popular CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid.

marijuana stocks

mCig, Inc. (MCIG)
1,265%

A company that we’ve kept up with for the better part of the last year, MCIG became another clear example of what marijuana stocks have started to look like after Donald Trump was elected President. The company has been making many key strides over the last few months including posting some of its best numbers in history.

This includes MCIG currently holding over $10 million in order/contract backlog (as of their last PR in December). In similar fashion to OWCP, shares of MCIG saw a bump in late October when the stock moved from under $0.04 to as high as $0.218. After consolidating in early December, MCIG manage to rally strong heading into the end of the year and recently hit highs of $0.505.

cannabis stocks

Axim Biotechnologies, Inc. (AXIM)
3,941%

Another company that we’ve been following very closely, this has been one of the biggest runners of the year amid heavy volatility. Another cannabis biotech, the company focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. MJNA is also an investor in AXIM.

In late October the stock was trading just under $0.50 moved to a high of $10 before consolidating to levels between $7.50-$8. Wouldn’t you know it, heading into the beginning of 2017 the stock broke the sideways trend and moved to highs of $19.80.

cannabis stock

Vitality Biopharma (VBIO)
361%

A company that many of us are familiar with, this cannabis biotech had a smaller run a few weeks before we started picking up coverage. In early October, the stock moved up from around $0.92 to highs of $1.84. After pulling back to lows in December, we began looking at this company at $0.98 and watched as it ran to highs of $4.24. The company is a cannabis biotech focusing on treating disease through its prodrug utilizing cannabinoids for the treatment of serious neurological and inflammatory disorders.

marijuana

Cannabis Science (CBIS)
469%

The company specializes in the development of cannabinoid-based medications and recently announced a collaborative research agreement with Dana Farber/Harvard Cancer Center. Their initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

From October 3 to October 19 CBIS jumped from $0.0169 to as high as $0.077. After pulling in during December, the stock kicked off the new year with a big bull run all the way to highs of $0.0961 for the year so far.

cannabis

Hemp Inc. (HEMP)
103%

One of the most vocal companies on Hemp production in the US, Hemp Inc. They’ve continued to push for a ubiquitous acceptance for all uses of the hemp plant for years now and have targeted North Carolina to grow over 3,000 acres of hemp.

“We are proud to collaborate with other American industrial hemp farmers as we now become part of the modern industrial hemp farming movement. This is a turning point for America and it’s a turning point for Hemp, Inc. Hemp, Inc. has the infrastructure in place to process millions of pounds of hemp fibers and stalks a year, on a commercial level. Our 70,000 square foot industrial hemp processing facility, on over 9 acres in Spring Hope, North Carolina, is the only one of this magnitude in North America. The industrial hemp crop is part of history in the making and it is something that will prove to be lucrative not only for the farmers in North Carolina but for Hemp, Inc. as well,” said CEO Bruce Perlowin in a recent PR.

HEMP saw a bump in volume early in October, the stock ran from $0.0276 to $0.056 before consolidating in late November/December, and has once again begun to aggressively climb back from that price channel.

hemp

Cannabis Sativa, Inc. (CBDS)
195%

With multiple subsidiaries, this company has products ranging from hemp oils & capsules to cannabidiol infused bottled water and even its own patented cannabis plan named Ecuadorian Sativa (Patent PP27,475). Back in late September the stock was trading around $2.80 per share before it jumped up to highs of $8.25. After consolidating for weeks leading up to the new year, CBDS has once again followed suit of many marijuana stocks having now climbed back above $8.

CBD

OH CANADA!

This leads us to our “neighbors up north” because we haven’t just seen a boom from US marijuana stocks alone. The trend has echoed into Canada with some of the most anticipated IPOs so far this year

Emblem Corp. (TSXVENTURE:EMC)(OTCQB:EMMBF)
55%

Emblem Corp, a Licensed Cultivator out of Paris Ontario is one of the most watched and anticipated offerings that has come out of Canada in the last few months. Beyond the fact that they are already growing cannabis and revenue producing investors have taken note of one of their founders and current President, a gentleman by the name of John Stewart.

No, not John Stewart from the Daily Show even though that would be awesome, John Stewart former CEO of Purdue Pharma one of the largest private biotech companies in the world and creators of OxyContin. We see the potential long term to create a cultivator/Biotech hybrid in which case Emblem could be the Next GW Pharma of Canada.

Marijuana IPO

InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) (CNSX: IN)
326%

This company has been following the same pattern as many of the other cannabis biotechs but also comes with what looks to be a stock promotion behind it. The company recently appointed Jeff Charpentier, CPA, CA as InMed’s Chief Financial Officer & Corporate Secretary as well as Martin Bott to its Board of Directors; Bott has worked at Eli Lilly & Company since 1988 and held a variety of roles in the U.S., Switzerland, Germany, and the UK.

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. IMLFF saw a rise in price early in October (shocker right?), a period of consolidation leading up to the new year, and since that ball dropped, the stock has been on the run moving from $0.10 in October to highs of $0.4261 just a few days ago.

Marijuana Stocks

Aurora Cannabis Inc. (TSXV: ACB) (OTCQB: ACBFF)
179%

The company’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada.

They just announced that the company has officially surpassed 12,000 registered patients within the first 12 months of product sales in Canada. They also announced that they had signed a Joint Venture Research Agreement with Radient Technologies Inc. (“RTI”). The first phase of this venture will include screening experiments of extraction conditions, while phase two includes larger scale experiments related to extraction throughput and optimal extraction conditions. Aurora’s scientists and the RTI team will commence tests January 16, 2017, and the first phase is expected to be completed within approximately six weeks, so something to keep an eye on here in our opinion.

Likewise with the other stocks, the market activity has followed suit even though Aurora has differed by not breaking a new high this year as compared to the high it made in November. But the new uptrend on the chart could be a key indicator for future potential. Since October (at $1.06), shares of ACBFF has seen two and possibly three clear runs; One that saw highs of $1.89 before consolidating, another that saw highs of $2.96 before consolidating, and possibly a new uptrend forming now in January.

Buy marijuana stocks

These are just a few marijuana stocks that have demonstrated a near identical move in the market both leading into the election and leading up to the inauguration. We’ve said it before and most likely will say it again: Marijuana Stocks can very much be event driven so something to keep in the back of your head as we watch 2017 unfold. As investors become more informed on the industry itself, we’ll keep our had on the pulse to find the real story behind some of the biggest marijuana stock moves in the market today.

 

 

 

 

 


 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. MAPH owns 2 million common restricted shares of mCig Inc. MAPH owns 10 million common restricted shares of Hemp Inc. An affiliate of MAPH owns 70,850 common restricted shares of Emblem Corp. We may buy or sell additional shares of any stocks mentioned, in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information

1 2977

Biotech Buzz Could Focus On Cannabis

San Francisco will be a hotbed for biotechnology this week. The annual JPMorgan Healthcare Conference kicks off on Monday the 9th and goes through Thursday the 12th. But this isn’t the only conference and there will surely be thousands of investors in the city to attend all kinds of presentations being made, which are focused on biotechnology & healthcare. Outside of just JPM’s conference, the crowd around Union Square also consists of the Biotech Showcase, which sets up at the Hilton San Francisco Union Square; and the OneMedForum across Post Street from the St. Francis.

Biotech_Showcase

There’s also the StartUp Health Festival on Montgomery Street and other conferences. Considering that thousands of people who aren’t going to invitation-only conferences like JPM, it would stand to reason that attention will be on the industry in full force this week.

Recently Vitality Biopharma (VBIO) announced that it would be presenting at the Biotech Showcase on Wednesday January 11th. The Showcase hosts over 2,800 attendees, over 5,600 one-on-one meetings, and will be expecting to see over 550 investors present.

Biotech Showcase™ is an investor and networking conference working to provide private and public biotech and life sciences companies with an opportunity to present to, and engage with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this week, which is widely viewed as setting the tone for the coming year…so JPMorgan is just the tip of the iceberg during San Fran’s biotech invasion.

“Biotech has historically outperformed the broader market during The J.P. Morgan Healthcare Conference,” biotech analysts at the firm wrote in a note to clients ahead of the event.

And we aren’t the only ones who could be seeing the potential “writing on the wall.” One of the presenters at the conference has even said, “…there’s a growing interest in medical cannabis among traditional health care institutions. This is a growing part of what is becoming mainstream health care.” As we said last week, even though we focus specifically on marijuana stocks, the biotech aspect of VBIO could be something to pay attention to heading into this week, considering the historic impact that the JPM conference (starts today) has had in the past for companies that have a stake in the space.

We said that this week could shed some light on many biotech companies including those involved with cannabis. Now we see that VBIO will be at ground zero, not just as another biotech company that could benefit from the shockwave but management will be in the exact location and presenting to the exact audiences.

Company CEO Robert Brooke will provide a 30-minute overview of Vitality Biopharma’s business during his presentation and will be available to participate in one-on-one meetings with registered attendees.

Event: Biotech Showcase Conference
Date: Wednesday, January 11, 2017
Time: 8:00 a.m. PT
Track: Room 8 (Ballroom Level)
Location: Hilton San Francisco Union Square, San Francisco, CA


 

 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of ( VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

    7 3109

    We’ve all come here for one reason: Getting Information on Stocks. With most marijuana stocks being considered penny stocks, there are many things that need to be taken into account because yes, they do have higher risk than something like Microsoft or Apple…at least during the early stages of development.

    A lot of the risk comes from volatility in markets. At the drop of a hat a penny stock can explode 20, 50, 100, or even 300% within the matter of weeks or even days. The important part to pay attention to during times of increased volatility is the chart. Historic levels of support and resistance can shed some light on where there are strong points on the chart that show where a price could hold up…especially during times of a pull-back. The main point, as with any stock, is not to let emotion dictate the pace and think logically.

    During times when you get a massive short squeeze and market makers basically need to give up and cover, the second day following a major squeeze needs to be followed closely. Unless there is another monster day of bullish momentum, there’s a good chance that short traders will short even heavier to attempt to make money back after losing “yesterday”. This could trigger some very volatile days to follow and many times, periods of pull-back. The major reason for the pull-back after such a big day has more to do with where the real “retail market” is.

    Obviously a stock can’t go up every day and needs to consolidate but after such a big day on the day of a short squeeze, the market needs to find where the true retail channel is. The point is to stay calm, don’t let emotions dictate the pace. After you see such a big short squeeze, a healthy market will need to find its real base. Keep in mind that most of the time there is a short squeeze, there’s typically more buying coming from short traders and not necessarily retail buying directly. It’s normal to see a pull-back so it’s best to remain calm and pay attention to the historical levels of support and resistance.

    For example if a stock is trading around $2.50-$3.00 consistently and shows clear resistance levels around $3, there’s a good chance that a short is beginning to build in that area. Now say a short squeeze triggers, and that stock has a move above $4; that big move doesn’t necessarily mean that the market is at $4, it could just mean that there wasn’t enough resistance to hold back the price during the time that short sellers needed to buy back shares to cover their short position. Keep in mind that shorting deals with borrowing shares and not borrowing price. What we mean is that if you short a stock, you essentially are borrowing a number of shares of stock and when you need to cover your short, you need to pay back those shares.

    If you were short 100 shares at $2 and now the price is at $4 when you have to cover your short position, you would have been forced to pay double the price in order to pay back your position. This is why we say that a short squeeze doesn’t necessarily represent the true retail market. Again, there can be a lot of volatility following a short squeeze that includes panic selling and heavier shorting so it’s important to stay calm and pay close attention to the trend, sometimes cost averaging at lower prices, or even holding strong as another short squeeze could trigger. All things considered, the final decision is up to you but you should take into account these other factors especially when there is a giant spike in price and volume. A healthy market will not go up every day and taking advantage of the volatility can be where a lot of money could be made.

      0 1192

      The MoneyShow San Francisco

      Cannabis Investors looking to attend (for Free) the San Francisco Money Show from August 23rd to August 25th need only Register here. The event is not just related to Cannabis Investments, but everything from Bit Coin to Private Technology. To Register for Free Click this link:

      https://www.cannabisinvestingevent.com/expert-details.asp?speakerid=1010534SPK&scode=041752

      The 35th annual MoneyShow San Francisco brings together the most forward-thinking minds in finance and technology. This year, we are focused on exploring successful strategies, disruptive technologies, and next-level thinking that’s relevant to individual investors. Whether you’re new to the investing world or looking to discover the next Facebook or Google, you won’t want to miss the opportunity to meet and engage with 65 of the nation’s leading money experts and thousands of like-minded investors just like you!
      There’s something for everyone at The MoneyShow San Francisco—from fine¬-tuning your strategies and mastering the latest concepts to simply learning more about investing from some of the best minds in the industry.

      Why Attend

      • Access to 65 of the nation’s leading investment experts who will share their take on where the markets are headed, where to find bargains, and how to stay ahead of the curve.

      • Over 160 FREE high¬-quality educational workshops & “must¬ attend” keynote presentations at Opening Ceremonies.

      • Lively & interactive exhibit hall that will feature 100+ leading financial service companies showcasing their products and services.

      • Countless opportunities to meet & network with thousands of other investors with similar interests and goals in one location.

      https://www.cannabisinvestingevent.com/expert-details.asp?speakerid=1010534SPK&scode=041752

        0 1124

        Untitled Extract Pages1 Untitled Extract Pages2 Untitled Extract Pages3 Untitled Extract Pages4 Untitled Extract Pages5 Untitled Extract Pages6 Untitled Extract Pages7 Untitled Extract Pages8

          3 5582

          For the past several years & definitely in 2015 Marijuana stocks are some of the most talked about in today’s market. What was once taboo just a few years ago is now on the tip of everyone’s tongue? No matter if it’s speculation or forthright belief that this is the next industrial revolution, if you trade stocks, the question of “Should I invest in pot stocks?” has probably crossed your mind at least once in the last 18 months. So where are we after a little over a year following legalization of marijuana in half the US (in some shape or form)?

          Hundreds of new marijuana companies are popping up in the public space. Marijuana Stocks have become some of the most talked about in the market with many of them being considered penny stocks. Low priced and emerging growth companies have taken center stage and while larger companies like GW Pharmaceuticals (GWPH) and Insys Therapeutics (INSY) forge ahead with their use of marijuana as a viable option for biotechnology applications, these relatively smaller companies have broadened the market to not only include production of the actual plant but to also include ancillary services like security systems, consulting services, marijuana storage & preparation products, even in the beverage industry. There’s no denying the potential in the marijuana business. Alcohol and tobacco companies bring in billions of dollars in sales and profit every year so with such a green industry, why shouldn’t there be an Anheuser-Busch InBev (BUD) or Altria (MO) of pot?

          Furthermore, it’s not just the average penny stock investor buying these pot stocks. Wall Street Analysts have begun coverage of several marijuana companies and several well-known investment firms have begun to put money into pot. Fidelity, Federated (FII), Janus (JNS) and BlackRock (BLK) are just a few of these firms. Many pot stocks have had an err of negativity not only due to conservative opposition politically but also because of the huge spikes that 2014’s first quarter showed. Now that the investment community has become well aware of the risks involved (especially after so many pot stocks were halted last year), many of the marijuana stock trading in the market today have actually been better from a longer term perspective (when the typical 2014 investor focused on the 2-day or 2-week flip).

           

          The Good

          I took at look over a period of 6 months from December of 2014 to May 2015 to see if a buy and hold strategy with pot stocks would start making sense. In several cases, this approach to an investment in marijuana companies would have paid off. Totally Hemp Crazy (THCZ) was trading between $0.0057 and $0.0205 during the month of December. Over the course of these last 6 months, an investment at those levels and even much higher than that would have paid off handsomely. Assuming an average price during December of .009, THCZ shares have increased in price by as much as $0.311 after the stock hit highs of $0.32 in early April and then once again tested $0.30+ right before May. A buy and hold strategy would have shown a potential profit of nearly 3,500%…and the current 6 month trend for this pot stock remains in a positive direction.

          Pot Stock investments centered in the biotech space have been ever growing especially for cancer therapies. Oxis International (OXIS), GW Pharmaceuticals (GWPH), and Insys Therapeutics (INSY) all focus in this specific segment and all three have seen significant price appreciation since December. Oxis has gone from having a caveat emptor on OTC markets in December to just filing a 14-C to lay groundwork for a reverse split that “The Board believes…may be desirable because it could assist the Company in meeting the requirements for initial listing on NASDAQ by helping to raise the bid or closing price for our common stock.”

          From trading between $0.0131-$0.018 in December, shares of Oxis have increased by as much as 434%. In a similar fashion, but at much higher prices, GW Pharma and Insys have also enjoyed a health dose of price movement. GW from late December lows around $65 to recent late April highs of $126.78 and INSY from around $35 at the beginning of December to highs in April of $67.87. In fact less than 3 weeks ago, INSY posted its earnings which not only showed a increase in net rev by nearly 70% but it also showed that the company had more than $70m in cash at the end of the first quarter in comparison to just over $40m in the same period of 2014.

          Even the agricultural space is breaking ground for pot. CannaGrow Holdings (CGRW) and Two Rivers Water and Farming Co (TURV) was trading at $0.4427 in mid December and has just recently hit new 6-month highs this week at $0.96. The company’s subsidiary, GrowCo was founded in May of last year and provides green houses to marijuana farmers throughout the US. For Cannagrow, the stock price has jumped from around $0.20 in December to as high as $1.05 earlier this year. Both stocks have maintained price above their previous channels in December.

           

          The Bad

          Unfortunately this is still the stock market and with much speculation, can come high risk. Pot stocks aren’t all bright and shiny; in fact many have fallen incredibly fast over the last 6 months. The main contributing factor, which has stifled progress has many times been the companies themselves. Through toxic financing or even the simple lack of moving from the development stage to the working stage has caused many of the “would be” bullish marijuana stocks to react negatively in the market. MaryJane Group (MJMJ) for instance, has a working property in Colorado; a Bud And Breakfast. However, due to heavy dilution in the market this stock has declined by almost 100%. For this in particular, MJMJ was trading at $0.50 in November of last year and today’s prices show the stock trading at less than a penny! Even with what appears to be positive press, the dilutive nature in the market seems to have forced this stock to become a quick trade as opposed to a “buy and hold” pot stock.

          Creative Edge Nutrition (FITX) has been riddled with curiosity on the truthfulness of the company’s management and has even raised international eyebrows as of late. I know I’ve been looking from a 6-7month time frame but FITX may take the cake after getting hammered for the better part of the last year. A once $0.10 stock, now trades at roughly half a penny. Medbox Inc (MDBX) has also fallen victim to the riggors of selling pressure. Since early December, shares of MDBX (once trading above $8/share) have fallen to new all time lows in May. A decrease in revenue compared to that of Q1 2014, net loss nearly tripling, and millions of dollars still left in its “notes payable” section on the balance sheet can’t be helping things especially when or if these note in particular come time to convert at low prices.

          Even though it wasn’t trading any higher than $0.0074 since December, heavy dilution and what many are saying “broken promises” have forced Vapor Group Inc (VPOR) stock to tumble to all time lows of $0.0008. Filings are delinquent, the stock is trading with three zeros before any kind of share price and yet another increase in its authorized shares from 4.5 BILLION to 8 BILLION, following at May 21 8K filing. This is just an example of what can happen with small cap companies especially when the potential could be there. Vapor Group financials show from its 2014 10K that the company is producing revenues and showed a gross profit margin of 68%! Where’s the disconnect?

           

          The “Buzzy”

           As you know, pot stocks have been heavily “pumped” not only by newsletters but by individual investors on social media & message boards. Nothing wrong with that in my opinion but with buzz can come uncertainty so it’s important to pay attention to who’s saying what and why they are saying it. The blatant “pumpy” nature of some of these people simply has no weight to back up any of their lofty statements BUT if you have a company that has released good news and the buzz is a result of a technical set up or company event, the buzz can be a real catalyst for gains.

          Recently several companies have begun to take hold in the social media world and have garnered much more attention in comparison to previous months. FBEC Worldwide (FBEC) has been gaining more appeal after a similar company (mentioned above) found massive success in the hemp infused beverage market. Dubbed as “an upcoming beverage company with intellectual property formulas and marketing capability for production and distribution of proprietary supplements, beverages, and H.E.M.P. Energy shot-drinks”, FBEC seems to be building from the inside out starting with its development team. Just recently the company announced that it entered into a Letter of Intent with G. Randall & Sons Inc, who’s co-founder Linda Strause, Ph.D., has “an extensive 30-year background in clinical science with biotech companies.” Since April, the stock has seen highs of $0.09, up from previous lows of $0.01. Now that it appears volume has become a bit more consistent, this stock labeled by many as a “low float play” has increased in price 1,300 after pulling in to $0.004.

          Pazoo Inc (PZOO) has also been “buzzing” in the twittersphere. Announcements in March sparked speculation and somewhat of a stamp of approval by investors and traders after seeing that the company has been pushing toward more progress for marijuana testing (something that to me has been overlooked in all of the marijuana industry progress). Furthermore, the company also recently announced the payoff of roughly $400k in convertible notes which could have potential been a larger source of dilution to Pazoo’s relatively liquid market. Since March, share price for this pot stock has increased from a low of $0.004 on March 11 to highs of $0.0204 just before the close of April.

          Also creating some buzz has been app company Mass Roots (MSRT). The company has received acclaim from not just the trading community but from news organizations like CNN, CNBC, Fortune, and The New York Times. Businesses can use MassRoots to advertise their goods and services to cannabis consumers and based on the stock price being above $1 (unlike many of the other marijuana stocks on the market), MSRT has gained attention from other investors who otherwise would not “play” a stock below that price threshold. In a recent press release, the company announced that MassRoots now has 174 of the 510 dispensaries in Colorado, or 34.1%, using its network to keep their customers updated. According to Massroots, these 510 dispensaries in Colorado did $699.2 million in cannabis sales according to the Colorado Department of Revenue, during 2014. Though share price and volume have been relatively light, buzz surrounding this stock has increased so this could be something to keep an eye on. It wasn’t that long ago that MSRT was trading above $7/share.

           

          Conclusion

          In the end, your decision to buy pot stocks or sell pot stocks is something only you can make. The risks are evident, the opportunity is apparent, and the best part of all of this is that there are still untapped markets throughout the United States due to legalization; or lack there of. Whether you’re looking for the right marijuana stock to buy or you’re just simply interested in pot stock news, this is just a brief over view of what I have seen during the evolution of the industry as a whole.

            2 2819

            You’ve likely referred to them as “Marijuana stocks,” or “cannabis stocks” or maybe heard a friend call them “Pot Stocks.” What ever they go by, there’s no denying that the subject of Marijuana Stock investing is a topical one. Ten years ago if you told your parents you were getting into “marijuana” they would have had you pee in a cup, now it seems dad & his poker buddies or mom in the PTA are saying “How do I get into weed?”

            Today we see that the business of marijuana is not just one of cultivation and distribution. There are finance companies, consulting firms, industry analysts, security firms, real estate companies, biotechnology, tech start-ups, social media companies all involved in some ancillary vertical associated with cannabis. As the marketplace continues to grow (pun intended) we are seeing well-established industries entering the sector.

            Within the capital markets public companies keep sprouting from, it seems, out of nowhere to try and carve out their own green footprint. Cannabis stocks, as volatile as they may be, continue to captivate investors looking to grab their own piece of a brand new industry, the same way their parents did ten plus years ago with “DotCom.” Dot Bong seems to be the millennials’ turn at finding the next Ebay or Amazon. Think about it, if you could have invested in alcohol just as prohibition was ending, would you (assuming that there was an opportunity to purchase shares of a publicly traded alcohol company)? I will be presumptuous and say “yes”f or you; and that’s exactly what’s happening. Marijuana is the newest “sin” sector in the public markets, joining the likes of big tobacco, Alcohol, and Gaming industry.

            So do you know how to buy cannabis stocks VS others? It’s very simple and is the same way you would purchase shares of Coca-Cola if you wanted to. The only difference is that most of these stocks will trade on the OTC or “Over The Counter” and regulatory issues could be an obstacle for some who are looking to invest in marijuana stocks. Information is everything and being able to take on the due diligence process is of the utmost importance before considering a cannabis stock as an investment.

            A new report out from investment app SigFig shows that 1 in 8 investors have purchased so called “sin stocks”, with 7% of investors buying into tobacco companies. More than 2% of investors have been shown to support marijuana companies; while just under 2% of investors go into both casino gambling and alcohol. A new breed is rising in the market especially when considering an investment into cannabis. “Stuffy” tobacco investors are older and generally live in the South, while investors in this “new crop” of marijuana companies are more likely to live in the Northeast such as in the New York tri-state area.

            But here’s the kicker, people are always talking about “younger generations not putting money into the stock market”. But if you take a look into this study, it shows that far and away the disparity between the ages of marijuana stock investors and other “Sin stock” investors is incredibly evident.

            Sin Stocks

            The “less money” to invest is exactly what has kept many flocking to cannabis stocks to watch. Take our own Wolf of Weed Street for example, along side thousands of others who were able to take a small investment and make it work for them in BIG ways. While many of these older investors choose to lay their money up for months or even years to find a return of 10-15%, many marijuana stocks have returned 50-5,000% in the matter of days or weeks…that’s not to say that there is typically much more risk involved with small cap marijuana stocks VS the much larger tobacco and casino giants.

            When the discussion about marijuana stocks comes about, where do you stand? Do you find yourself in the same mindset of at least 7 high net worth investment funds taking the leap into buying cannabis stocks or are you still watching from the sidelines? Let us hear your thoughts below

            Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

            We are your #1 source for all things Marijuana Stocks, Subscribe Below!

            Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
            Ad Placements